SCHEMBL4180313

SCHEMBL4180313

Cc1ccc(-c2cc3cnc(NN4CC5CCCC5C4)nc3n(C)c2=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 5/20 0.47
SRC P12931 3/20 0.47
ABL1 P00519 2/20 0.47
MAPK14 Q16539 2/20 0.47
EGFR P00533 2/20 0.47
PDGFRB P09619 1/20 0.47
PDGFRA P16234 1/20 0.47
RIPK2 O43353 4/20 0.43
ACVR1 Q04771 1/20 0.43
WEE1 P30291 3/20 0.42
LCK P06239 1/20 0.42
TNK2 Q07912 1/20 0.42
STK4 Q13043 1/20 0.42
STK3 Q13188 1/20 0.42
SIK2 Q9H0K1 1/20 0.42
STK26 Q9P289 1/20 0.42
STK24 Q9Y6E0 1/20 0.42
NOD2 Q9HC29 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4192757 0.91 RIPK2 (0.53) FGFR1SRCABL1MAPK14EGFR
SCHEMBL4179272 0.91 MAPK14 (0.48) FGFR1SRCABL1MAPK14EGFR
SCHEMBL4182714 0.89 FGFR1 (0.48) FGFR1SRCABL1MAPK14EGFR
SCHEMBL4178720 0.89 FGFR1 (0.47) FGFR1SRCABL1MAPK14EGFR
SCHEMBL13951206 0.89 FGFR1 (0.44) FGFR1SRCABL1MAPK14EGFR
SCHEMBL4181176 0.88 FGFR1 (0.42) FGFR1SRCABL1MAPK14EGFR
SCHEMBL4181014 0.85 WEE1 (0.51) FGFR1SRCABL1MAPK14EGFR
SCHEMBL4171282 0.85 FGFR1 (0.52) FGFR1SRCABL1MAPK14EGFR
SCHEMBL4176329 0.85 FGFR1 (0.47) FGFR1SRCABL1MAPK14EGFR
SCHEMBL13928692 0.83 WEE1 (0.51) FGFR1SRCABL1MAPK14EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090036472-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-02-05 US claimed
EP-1846403-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-10-24 EP claimed
WO-2006082492-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-08-10 WO claimed
US-20090036472-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-02-05 US disclosed
US-20090036472-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-02-05 US disclosed
US-20090036472-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-02-05 US disclosed
EP-1846403-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-10-24 EP disclosed
WO-2006082492-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036472-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS IL1B, TPMT, IL1R1 FGFR1 2037/4885SRC 3064/4885ABL1 3754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.